Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus

o1853_all

WEKO3

lat lon distance

[[sub_check.contents]]

[[sub_radio.contents]]

Field does not validate

[[sub_attr.contents]]　

o1853_all.pdf

https://fukuoka-u.repo.nii.ac.jp/record/5133/files/o1853_all.pdf

application/pdf

ファイル	ライセンス
o1853_all.pdf (890.6 kB) sha256 088969498127f91f57c12366c262c8f2924259fda4746e424a273616716e1056

2020-11-13

Version	Date Modified	Object File Name	File Size	File Hash Value	Contributor Name	Show/非表示

Downloads

Plays